High-bias stability of monatomic chains

For the metals Au, Pt and Ir it is possible to form freely suspended monatomic chains between bulk electrodes. The atomic chains sustain very large current densities, but finally fail at high bias. We investigate the breaking mechanism, that involves current-induced heating of the atomic wires and electromigration forces. We find good agreement of the observations for Au based on models due to Todorov and coworkers. The high-bias breaking of atomic chains for Pt can also be described by the models, although here the parameters have not been obtained independently. In the limit of long chains the breaking voltage decreases inversely proportional to the length.Comment: 7 pages, 5 figure

Franck-Condon Physics in A Single Trapped Ion

We propose how to explore the Franck-Condon (FC) physics via a single ion confined in a spin-dependent potential, formed by the combination of a Paul trap and a magnetic field gradient. The correlation between electronic and vibrational degrees of freedom, called as electron-vibron coupling, is induced by a nonzero gradient. For a sufficiently strong electron-vibron coupling, the FC blockade of low-lying vibronic transitions takes place. We analyze the feasibility of observing the FC physics in a single trapped ion, and demonstrate various potential applications of the ionic FC physics in quantum state engineering and quantum information processing.Comment: 7 pages, 5 figure

Phonon-assisted Kondo Effect in a Single-Molecule Transistor out of Equilibrium

The joint effect of the electron-phonon interaction and Kondo effect on the nonequilibrium transport through the single molecule transistor is investigated by using the improved canonical transformation scheme and extended equation of motion approach. Two types of Kondo phonon-satellites with different asymmetric shapes are fully confirmed in the spectral function, and are related to the electron spin singlet or hole spin singlet, respectively. Moreover, when a moderate Zeeman splitting is caused by a local magnetic field, the Kondo satellites in the spin resolved spectral function are found disappeared on one side of the main peak, which is opposite for different spin component. All these peculiar signatures that manifest themselves in the nonlinear differential conductance, are explained with a clear physics picture.Comment: 12 pages, 6 figure

Ezetimibe added to statin therapy after acute coronary syndromes

BACKGROUND: Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascular events further is not known. METHODS: We conducted a double-blind, randomized trial involving 18,144 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and had LDL cholesterol levels of 50 to 100 mg per deciliter (1.3 to 2.6 mmol per liter) if they were receiving lipid-lowering therapy or 50 to 125 mg per deciliter (1.3 to 3.2 mmol per liter) if they were not receiving lipid-lowering therapy. The combination of simvastatin (40 mg) and ezetimibe (10 mg) (simvastatin-ezetimibe) was compared with simvastatin (40 mg) and placebo (simvastatin monotherapy). The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization ( 6530 days after randomization), or nonfatal stroke. The median follow-up was 6 years. RESULTS: The median time-weighted average LDL cholesterol level during the study was 53.7 mg per deciliter (1.4 mmol per liter) in the simvastatin-ezetimibe group, as compared with 69.5 mg per deciliter (1.8 mmol per liter) in the simvastatin-monotherapy group (P<0.001). The Kaplan-Meier event rate for the primary end point at 7 years was 32.7% in the simvastatin-ezetimibe group, as compared with 34.7% in the simvastatin-monotherapy group (absolute risk difference, 2.0 percentage points; hazard ratio, 0.936; 95% confidence interval, 0.89 to 0.99; P = 0.016). Rates of pre-specified muscle, gallbladder, and hepatic adverse effects and cancer were similar in the two groups. CONCLUSIONS: When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes. Moreover, lowering LDL cholesterol to levels below previous targets provided additional benefit